Michael H. Rosove, MD; Wayne W. Grody, MD, PhD
The U.S. Food and Drug Administration modified warfarin labeling in 2007 to suggest, but not mandate, pharmacogenetic testing. Genetic analysis is now commercially available. However, results predict only one third of all dosing variation, the value of testing in reducing bleeding and thrombosis rates remains unproved, and cost-effectiveness is not established. Careful consideration of clinical factors that influence dosing, conscientious prothrombin time monitoring, and sage dosage adjustment remain paramount in warfarin management. Further study is required before routine warfarin pharmacogenetic testing can be recommended.
Michael H. Rosove, Wayne W. Grody. Should We Be Applying Warfarin Pharmacogenetics to Clinical Practice? No, Not Now. Ann Intern Med. 2009;151:270–273. doi: 10.7326/0003-4819-151-4-200908180-00009
Download citation file:
Published: Ann Intern Med. 2009;151(4):270-273.
Healthcare Delivery and Policy, Prevention/Screening.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use